What is the official website of Novartis ?

The official website of Novartis is http://www.novartis.com.

What is Novartis's cybersecurity risk score?

Novartis has an AI-generated cybersecurity risk score of 811 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Novartis experienced?

According to Rankiteo, Novartis currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis is not certified under SOC 2 Type 1.

Does Novartis have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis does not hold a SOC 2 Type 2 certification.

Does Novartis comply with GDPR ?

According to Rankiteo, Novartis is not listed as GDPR compliant.

Does Novartis have PCI DSS certification ?

According to Rankiteo, Novartis does not currently maintain PCI DSS compliance.

Does Novartis comply with HIPAA ?

According to Rankiteo, Novartis is not compliant with HIPAA regulations.

Does Novartis have ISO 27001 certification ?

According to Rankiteo,Novartis is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis operate in ?

Novartis operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis have ?

Novartis employs approximately 86,785 people worldwide.

Does Novartis own any subsidiaries ?

Novartis presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis have ?

Novartis's official LinkedIn profile has approximately 4,751,735 followers.

What is the NAICS classification code for Novartis ?

Novartis is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis have a Crunchbase profile ?

No, Novartis does not have a profile on Crunchbase.

Does Novartis have a LinkedIn profile ?

Yes, Novartis maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis.

How many cybersecurity incidents has Novartis experienced ?

As of August 10, 2026, Rankiteo reports that Novartis has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis have ?

Novartis has an estimated 5,727 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis

Boost Score +25 with badge (5 left)

811

/1000

Good

836

/1000

Good

Novartis Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Novartis A.I CyberSecurity Scoring

Scoring History

Novartis

Novartis CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis has 34.64% fewer incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

Novartis has 2.91% fewer incidents than the average of all companies with at least one recorded incident.

Incident Types Novartis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Novartis reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 0 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.

Incident History - Novartis (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Subsidiaries

Novartis

Pharmaceutical Manufacturing

Website: http://www.novartis.com

Company Size: 10,001+ employees

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Loading…

Novartis Similar Companies

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

Novartis CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

August 03, 2026 03:05 PM

Amgen says patient health data, IP stolen in cybersecurity breach

Hackers recently accessed Amgen's cloud environment, stealing patient health information and proprietary company data,...

Read Article

July 28, 2026 02:40 PM

Cognizant Bags 5-Year IT Operations Deal With Novartis

Cognizant has secured a five-year contract to manage IT operations for global pharmaceutical giant Novartis. The partnership will use...

Read Article

May 21, 2026 07:00 AM

BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus

Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more.

Read Article

May 20, 2026 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

May 06, 2026 07:00 AM

Review cyber risks in 2 months: RBI to banks

Reserve Bank of India asks banks to review cybersecurity readiness within two months amid rising AI-driven threats and system...

Read Article

April 15, 2026 07:00 AM

Who is Vas Narasimhan, the Indian-origin Novartis CEO who joined Anthropic's board

The Indian-origin pharma executive is the first healthcare professional to sit on the board of the AI startup and his appointment points to...

Read Article

March 25, 2026 07:00 AM

Novartis sued for allegedly leaking data on breast cancer patient to Google, Contentsquare

In a lawsuit seeking class action status, a woman identified as “P.M.” said she began using the website for Kisqali, a Novartis breast...

Read Article

March 24, 2026 07:00 AM

Novartis Sued Over Tracking Pixels on Drug-Discount Websites

A Vermont breast cancer patient sued Novartis Pharmaceuticals Corp. for allegedly sharing her health information with Google LLC and other...

Read Article

March 23, 2026 07:00 AM

Novartis Faces Class Suit Over Patient Health Info Disclosure

Drugmaker Novartis collected patients' personal and health information through pharmaceutical marketing websites and transmitted it to third...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-19374

SUMMARY

A security vulnerability has been detected in adafap api-mcp up to 92b9a5d04acfec165c7d4ef852496593aa87be06. This affects the function customAxios of the file app/api/proxy/route.ts of the component Proxy API Endpoint. The manipulation of the argument url leads to server-side request forgery. The attack is possible to be carried out remotely. This product adopts a rolling release strategy to maintain continuous delivery. Therefore, version details for affected or updated releases cannot be specified. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-09

Updated

Date2026-08-09

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-19373

SUMMARY

A weakness has been identified in PhialsBasement KoboldCPP-MCP-Server 1.0.0. Affected by this issue is the function makeRequest of the file src/index.ts of the component BaseConfigSchema. Executing a manipulation of the argument apiUrl can lead to server-side request forgery. It is possible to launch the attack on the local host. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-09

Updated

Date2026-08-09

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-19372

SUMMARY

A security flaw has been discovered in Handwriting-OCR handwriting-ocr-mcp-server 0.1.0. Affected by this vulnerability is the function fs.readFileSync of the file src/index.ts of the component upload_document. Performing a manipulation of the argument File results in path traversal. Attacking locally is a requirement. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-09

Updated

Date2026-08-09

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-19371

SUMMARY

A vulnerability was identified in Nikolaibibo claude-comfyui-mcp 1.0.0. Affected is the function copyFileSync of the file src/tools/utils.ts of the component comfy_upload_image. Such manipulation of the argument image_path leads to path traversal. An attack has to be approached locally. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-09

Updated

Date2026-08-09

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12372

SUMMARY

A Server-Side Request Forgery (SSRF) vulnerability exists in nltk/nltk versions 3.9.4 and the current develop branch. The `nltk.pathsec.validate_network_url()` function, intended to prevent SSRF by rejecting internal network addresses, fails to reject IPs in the RFC 6598 shared address space (`100.64.0.0/10`). This occurs because Python's `ipaddress` module does not classify such addresses as `is_private` or `is_global`, and the current guard only checks `is_private` and a few explicit categories. An attacker who can influence a URL passed to NLTK's network-loading helpers can exploit this vulnerability to make a strict-mode application send requests to shared-address-space hosts, potentially exposing non-public infrastructure reachable from the application host. The impact is limited to SSRF-style confidentiality exposure, with no code execution claimed.

Published

Date2026-08-09

Updated

Date2026-08-09

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.0/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

https://huntr.com/bounties/2911b643-571c-42e4-b0c2-9a1fa6f491db

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…